Outlook on the Meal Kit Delivery Services Global Market to 2030: Online Segment Accounted for the Largest Revenue Share of More Than 63.2% in 2021
21 avr. 2022 06h43 HE
|
Research and Markets
Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Meal Kit Delivery Services Market Size, Share & Trends Analysis Report by Offering (Heat & Eat, Cook & Eat), by Service (Single,...
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
06 avr. 2022 08h30 HE
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to Explore MTD NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune...
New Report Finds Major Gaps in Child Care Policies for Food Allergy Nationwide
25 févr. 2022 06h50 HE
|
Asthma and Allergy Foundation of America
Washington, D.C., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Today, the Asthma and Allergy Foundation of America (AAFA) and the Elijah-Alavi Foundation (EAF) released “Child Care Policies for Food Allergy:...
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
08 févr. 2022 08h30 HE
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Four Dose Levels in Cohort 1 Patient Treatment Now Ongoing in Fully Enrolled Cohort 2 Intrommune Launches Series B Financing NEW YORK, Feb. 08, 2022 (GLOBE...
Allergy Immunoassay Market Brief: Sophistication in Testing is Leading to More Automated Effective Testing
25 janv. 2022 05h23 HE
|
Research and Markets
Dublin, Jan. 25, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunoassay Brief" report has been added to ResearchAndMarkets.com's offering. Allergies are a number of conditions that are caused by...
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships
21 déc. 2021 09h39 HE
|
Intrommune Therapeutics
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
AllerSmart IgE Allergy Testing Now Available for At-Home or At-Clinic and Includes the 9 'Big Foods' and 29 Key Environmentals
26 nov. 2021 09h00 HE
|
AllerSmart IgE
VICTORIA, British Columbia, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Covid 19 has dramatically impacted the healthcare industry and as such, antibody diagnostics have quickly evolved and gained...
Intrommune Participates in the Forsyth dentech 2021 Conference
22 sept. 2021 09h30 HE
|
Intrommune Therapeutics
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
Intrommune Therapeutics Appoints Gerard Kugel, D.M.D., M.S., Ph.D. to its Scientific Advisory Board
21 sept. 2021 09h30 HE
|
Intrommune Therapeutics
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
Global Allergy Treatment Markets Report 2021-2026: Allergy Therapeutics and ALK-Abello Dominates the Immunotherapy Segment
21 sept. 2021 05h53 HE
|
Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "Allergy Treatment Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The allergy treatment...